Welcome to our dedicated page for Ocular Therapeut SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ocular Therapeutix, Inc. (NASDAQ: OCUL) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including 8-K current reports and other documents filed with the U.S. Securities and Exchange Commission. These filings give detailed insight into Ocular Therapeutix’s clinical programs, financing activities, and key corporate events as it advances ophthalmic therapies based on its ELUTYX bioresorbable hydrogel technology.
Recent 8-K filings describe the structure and status of the AXPAXLI (OTX-TKI) registrational trials in wet age-related macular degeneration (wet AMD), including the SOL-1 and SOL-R Phase 3 studies, as well as plans for the SOL-X long-term extension trial. They also outline the design of the HELIOS-2 and HELIOS-3 Phase 3 trials in non-proliferative diabetic retinopathy (NPDR), the use of a novel ordinal diabetic retinopathy severity score (DRSS) endpoint, and Special Protocol Assessment (SPA) agreements with the FDA.
Other filings cover capital markets transactions, such as the September 30, 2025 underwriting agreement for a large common stock offering, expected net proceeds, and the company’s view of its cash runway into future years. Additional 8-Ks furnish quarterly financial results press releases, describe inducement equity awards under Nasdaq Listing Rule 5635(c)(4), and discuss notices of allowance from the U.S. Patent and Trademark Office related to AXPAXLI methods of use.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and can be paired with AI-powered summaries that explain the key points of lengthy documents like 8-Ks or registration statements in plain language. Users can quickly see how Ocular Therapeutix reports on trial designs, primary endpoints, regulatory interactions, cash resources, and potential patent protection. For investors tracking OCUL, this page is a central place to review official disclosures about clinical progress, financing arrangements, and other material events that may influence the company’s ophthalmology-focused pipeline and commercial product DEXTENZA.
Ocular Therapeutix (OCUL) filed a Form 3 disclosing the initial beneficial ownership of its newly appointed Chief Business Officer, Namrata Saroj. The filing reports direct ownership of 200,000 unvested restricted stock units (RSUs) that will vest in three equal annual installments beginning on the first anniversary of her start date.
Derivative holdings include 466,000 stock options spread across three grants: 50,000 options already fully vested at an exercise price of $9.95 expiring 02/27/2034; 100,000 options granted 02/28/2024 at $9.95 vesting 1/48 monthly after an initial one-year cliff; and 316,000 options granted 11/04/2024 at $10.27 with similar four-year vesting. All holdings are reported as direct ownership.
The filing is routine, conveys no operational or financial performance data, and does not imply the insider owns more than 10 % of outstanding shares.